PCYT2 mediates ovarian epithelial cancer metastasis by regulating cell membrane fluidity through the AMPK/FOXO1 signalling pathway.

This study investigates the role of phosphatidylethanolamine cytidylyltransferase 2 (PCYT2) in ovarian epithelial cancer, specifically examining its effects on cell migration and membrane fluidity. To achieve this, we will examine how the AMPK and FOXO1 pathways regulate these processes. Our analysis revealed a significant upregulation of PCYT2 expression in metastatic ovarian cancer tissues compared to primary cancer sites, which correlates with altered membrane fluidity. Our data indicate that PCYT2 is essential for modulating the invasive characteristics of ovarian cancer cells. It does this by regulating the expression levels of AMPK and FOXO1, suggesting its role as an upstream regulator in this signaling pathway. Experiments that either inhibit or enhance PCYT2 activity suggest that it may influence cancer cell infiltration by changing membrane fluidity. These findings provide valuable insights into the molecular mechanisms of ovarian cancer metastasis and highlight PCYT2 as a promising therapeutic target. Future research should validate these findings in larger cohort studies, and also explore the therapeutic potential of targeting PCYT2 in ovarian cancer treatment. In conclusion, although there have been substantial advancements in ovarian cancer therapies, the intricate nature of its metastatic behavior remains a major challenge. Our research clearly demonstrates the critical role of PCYT2, urging the scientific community to deepen their understanding of its involvement in cancer progression and to develop innovative treatment strategies.